The ongoing outbreak of Ebola in West Africa has raised a general awareness that at present there are no Ebola-specific medical countermeasures (MCMs) with proven effectiveness. Given the urgency of the situation and the desire to offer something that might be of benefit, a number of clinicians and healthcare organizations have suggested use of MCMs for which promising efficacy data in cell culture and animal model systems have been reported. Some of these investigational products have already been used under emergency authorizations to treat patients in Africa as well as patients evacuated to the United States or Western Europe. By their nature, these uses do not lead to the generation of sufficient data to assess safety and efficacy.
At the 6th International Filovirus Symposium held in Galveston, Texas, 30 March-2 April 2014, a workshop was conducted at which the most advanced MCMs under development for Ebola virus were discussed. Two previous state-of-the-art workshops, facilitated by the authors and others in September 2012 and March 2013, had focused on MCMs potentially available for human use following an accidental laboratory exposure to a BSL-4 agent. The process by which consensus positions were developed at those workshops regarding patient isolation and selection of MCMs to treat occupational exposures to Ebola is informative because it also forms the basis for MCM selection in the midst of the current Ebola outbreak. This manuscript describes the outcomes from those deliberations regarding the relative merits of different virus-specific MCMs for Ebola virus.
The first workshop, sponsored by the National Interagency Confederation for Biological Research (NICBR) [1] and held in Bethesda, Maryland, aimed at: (1) profiling the current postexposure contingencies in place at the BSL-4 laboratories in the United States and Canada, and (2) helping identify potential MCMs for the 3 category A pathogens identified by their laboratory directors as being of most concern: Ebola Zaire, the Arenaviruses, and Henipahviruses. This workshop was the first of its kind, embracing both interagency information exchange as well as sharing of public sector research. Among the participants were senior laboratory academic and government investigators working with these pathogens on countermeasures research, government scientists responsible for oversight of candidate drug development, infectious diseases specialists and other medical staff affiliated with all North American Biosafety Level 4 BSL-4 laboratories, and representatives from the Food and Drug Administration (FDA). The workshop focused on a review of the medical countermeasures presently under study for these 3 categories of agents as well as a discussion of the most important initial steps to be taken toward the goal of accelerating movement of the most promising candidates as potential options for use under approved regulatory mechanisms in the event of a potential laboratory exposure. While the body of research supporting the efficacy of currently known treatment or intervention options is not robust, it was felt that only through such active engagement with leading researchers, virologists, regulators, and medical experts in this field would the prospect of reaching consensus regarding the most promising interventional modalities be an attainable goal. It was hoped that such consensus would facilitate a prioritized development and prepositioning of those modalities most likely to fill what for the treating physician and affected employee had largely been a therapeutic void.
Prior to the meeting, a review of the published literature was performed to identify viable candidate countermeasures that had been evaluated in nonhuman primate (NHP) models and demonstrated to show some benefit through reported reductions in morbidity or mortality. In addition, a data call was performed with leading researchers and funding agencies to identify unpublished works. This information was summarized and shared with participants (Table 1 ). After review of animal studies and available data on safety in each category, workshop participants were asked to identify which medical countermeasures they felt held the most promise and/or offered the most favorable risk/benefit ratio at that time. In the case of Ebola virus, a number of different drugs or biologics were critically reviewed, and 3 different postexposure strategies were identified as being farthest along in development and/or believed to exhibit the greatest potential in animal studies thus far (Table 2): passive immunotherapy with monoclonal antibodies (MAbs) [7, 15] , postexposure vaccination with constructs involving viral vectors (such as vesicular stomatitis virus, VSV), and antisense compounds directly targeting the viral genome such as modified phosphorodiamidate morpholino oligomer (PMO)-based compounds [16] and small interfering RNA (siRNA) products [10] . It was well noted that much of the available data were generated by studies utilizing small numbers of animals, with different preparations of challenge material, at different facilities, and in some cases with NHPs belonging to different species. Despite the several challenges presented by comparative evaluation of the available data, consensus was reached that immediate efforts should focus on the development of the MAbs for use in a laboratory postexposure setting. This decision was influenced in large part by an established track record of safety with similar products in other diseases, the observed efficacy in available animal studies, the length of time after exposure that initiation of MAb therapy could be initiated while still observing a reduction in morbidity and mortality in the NHP model [7, 12] as well as what was envisioned to be an easier or perhaps more clearly defined regulatory pathway forward to advanced development.
In a follow-up meeting convened 11-12 March 2013 at the National Institutes of Health (NIH), the Working Group examined the current state of development of 2 candidate MAb products for Ebola virus (EBOV) exposure: MB-003 (USAMRIID/ Mapp Biopharmaceutical) and ZMAb (PHAC/Defyrus Inc.). Previously published data [7, 8, 17] as well as 2 new studies [12, 17] demonstrating the efficacy of these products in NHPs were reviewed. Importantly, these data were the first evidence that intervention and even treatment (as defined by initiation of an intervention after the onset of disease) appears achievable for EBOV. Inasmuch as timing of an intervention following a serious exposure may be critical in abrogating or modulating infection following a laboratory accident, these data provide the best evidence to date that there is a potential efficacious intervention that could be administered to laboratory workers within a reasonable time frame following a potential exposure. In addition, the data suggested the window to intervention could potentially be expanded further by the use of combination strategies. Given these findings, it was recommended that the potential for combination strategies be pursued, but independently of ongoing efforts to making MAbs available for contingencies in the near term. This strategy would allow evaluation of multiple candidate combination strategies (including combination of MAbs not only with interferon-based products but also with products that demonstrated efficacy when administered immediately or within the first hour following exposure) while not impeding or delaying the advancement or availability of the candidate MAbs.
It was also acknowledged that at the time of the meetings, none of the candidate MAbs had been approved as investigational new drugs (INDs) by the FDA. As such, the current availability of these candidate products as well as the potential access of these products was discussed. It was strongly recommended that the laboratories pursue pathways that could facilitate potential access to these compounds through an authorized emergency IND (eIND) or treatment IND mechanism or through an expanded access protocol involving multiple clinical centers supporting the nation's high-containment laboratories even in advance of a documented exposure. While it was evident that more studies of these products will be needed, in order to move these products forward on development and regulatory pathways, the developers and sponsors of these candidate products were strongly encouraged to prepare pre-IND packets and submit pre-IND meeting requests to the FDA. Once an IND is available, it was suggested that storage of such drug products in a central repository might be advantageous for rapid deployment in the event of an occupational exposure or outbreak situation.
In the subsequent Filovirus symposium in March-April 2014, the state of the art for Ebola MCMs was updated with the consensus options for potential use following an occupational exposure in the laboratory or healthcare setting ( Table 3 ). The choice of countermeasure(s) would be driven by multiple factors, including: time since exposure, availability, and potentially the current health status of the individual.
Since the Filovirus Symposium workshop in March-April 2014, the global response to the ongoing Ebola virus disease (EVD) outbreak has included a more comprehensive evaluation of MCMs for EBOV. Two recent reports, one from the World Health Organization [18] and the other from the European Medicines Agency [19] , summarize the state of the art. Both reports highlight the fact that those specific countermeasures with the most supporting efficacy data are in very limited supply, while those drugs licensed for other indications and therefore more available lack efficacy data in animal models. The reports emphasize the urgency of filling this knowledge gap while cautioning against uncontrolled clinical trials.
The medical countermeasures identified in these reports have been used recently in the United States and other developed nations in specialized facilities to which a small number of infected healthcare workers have been medically evacuated. Against a background of optimized standard of care (oSOC), there has been the introduction of several different investigational therapeutics as adjunctive therapy, ranging from the administration of convalescent plasma from recovered patients to the use of direct antiviral agents provided under eIND, as MCMs. The merit of conducting randomized clinical trials (RCTs) has recently been articulated for Ebola therapies [20] . Toward this end, the National Institute of Allergy and Infectious Diseases (NIAID) facilitated 2 closely spaced meetings in Bethesda in summer/fall 2014. As a consequence of those meetings, an RCT design proposed by NIAID and the FDA was adopted by the medical directors of the 3 high-containment patient care centers (Emory University Hospital, Nebraska Medical Center, and the NIH Clinical Center) in the United States that have cared for individuals medically evacuated from West While the investigators had at least some familiarity with most of the MCMs proposed for study in the context of an RCT, overall they felt that there were significant gaps in the group's mutual understanding of the preclinical and early clinical trial results supporting the potential utility of individual agents. Accordingly, they felt it was critical that in the second meeting the group undertake a comprehensive review of the available in vitro, animal (NHP and other animal model data) and early clinical data that the manufacturers have compiled about these individual agents in terms of their activity against EBOV. With this background, the investigator group invited company representatives of the lead candidates with putative antiviral or immune-enhancing activity against EBOV to present their products' supportive data, toxicity data, and early in-man experience.
The MCMs under consideration included the following:
• Convalescent or postimmunization plasma harvested from recent Ebola infection survivors: ▪ In time, it is possible that this category could potentially be expanded to include plasma donors who have participated in phase 1 anti-Ebola vaccine testing and whose plasma shows high neutralizing activity against the virus in animal or in vitro assays.
• zMapp triple monoclonal antibody cocktail from Mapp Biopharmaceutical: • Brincidofovir (CMX001) from Chimerix: ▪ An oral nucleotide analog with reportedly a more favorable toxicity profile than cidofovir and activity against DNA viruses that also has been shown in vitro to have activity against EBOV.
• BCX4433 from BioCryst: ▪ Viral RdRp inhibitor.
• AVI-7537 from Sarepta:
Over the course of that second meeting, these 7 products, including convalescent plasma, were individually reviewed and discussed with the sponsors, Afterward, a closed session was held in which the investigators discussed which of the products they felt had the strongest preclinical and early clinical data to support prioritizing its study within the context of an RCT in EVD patients. Important elements of this discussion included the following:
• It was again reiterated that the only scientific approach with a reasonable likelihood of being able to determine conclusively the potential therapeutic benefit or harm of a given experimental therapeutic adjunct is one in which that adjunct can be compared to a backbone of oSOC.
• There were no decisions made at this time to exclude any of the reviewed products for further consideration of inclusion within an RCT.
• Some of the products were less far advanced in terms of their preclinical development, and could potentially benefit from further animal and toxicity testing before being prioritized for immediate study within the proposed RCT.
• Not all of the data from ongoing or recently completed preclinical testing were available for each agent, and in at least 1 case allusion was made to preliminary animal test results that reportedly did not support activity of the agent in that particular animal model. Hence, subsequent, more complete knowledge of those findings could likely influence the prioritization of individual agents within the study queue.
• The molecular drift of the currently circulating EBOV that originated in Guinea (Makona variant) could theoretically lead to alterations in antiviral activity of some of the products under consideration. This is particularly true for the antisense strategies. Thus, future modifications of product toward contemporary variants may be necessary in some cases [21] . Subsequent to this workshop, Tekmira announced its intention to tailor its siRNA product for field trials in Guinea.
• The available or predicted drug supply of each of the agents varied from product to product, and the potential limited availability of certain agents would likely be an important factor in planning pairwise comparisons of products against oSOC, at least in the near term.
• The likelihood of quickly raising the oSOC available in West African Ebola treatment units to the level currently afforded in most US or European hospitals was deemed quite low. It was again emphasized that the most important outcome comparison to be made in an RCT was between the backbone oSOC, available in the individual setting, against the experimental MCMs being introduced as an adjunct to the oSOC.
With the considerations above in mind, the investigators concluded that they would be most supportive of initiating an MCM RCT beginning with ZMapp triple monoclonal antibody cocktail as the lead candidate for study. This was concluded despite the limited supply of this agent as well as the likelihood that only fairly limited quantities of this product would be capable of being produced until early in 2015. ZMapp is produced by Mapp Biopharmaceutical, Inc/LeafBio, Inc, and consists of a triple monoclonal antibody product that is manufactured in tobacco plants (Nicotiana benthamiana) and that is directed against the surface glycoprotein (GP) of EBOV. Among the most impressive preclinical data in the arena of Ebola therapeutics are data from an infectious challenge model in NHPs (rhesus macaques) showing that the ZMapp drug cocktail can prevent animals from dying, even when the product is administered as late as 5 days after an otherwise lethal challenge in that animal model (Table 3 ) [15] . In addition, there are anecdotal experiences with the use of 1-3 doses of this monoclonal cocktail in 8 different patients with EBOV who received this drug under the auspices of an eIND or other regulatory approval mechanisms. Of those 9 patients, some of whom received additional MCMs, 6 survived to resolution of their illness, whereas 3 died.
As a fallback to consideration of the use of ZMapp as the lead study candidate, the investigators recommended that convalescent plasma be prioritized as the second lead candidate for inclusion in the RCT. The reported survival of 7 of 8 EBOVinfected patients after transfusions of convalescent blood during the 1995 outbreak in Kikwit, Democratic Republic of Congo, is frequently cited as evidence that this is a viable treatment option [22] . Although passive immunization studies in experimentally infected NHPs have generally failed to demonstrate protective efficacy [23, 24] , concentrated intravenous immune globulin preparations have demonstrated some benefit [25] , and passive immunization is considered a viable option by some [26] . Recent experience has been obtained with convalescent plasma used to treat patients medically evacuated to the United States. Currently, 8 of 10 patients with EBOV treated in the United States have survived, and of those 9 survivors, 6 have received either infusions of whole blood or convalescent plasma as part of their adjunctive therapy in addition to other MCMs. These infusions have occurred at different times in their clinical illnesses, and from different sources of donor plasma. Four of the more recent 6 convalescent plasma recipients have received plasma infusions from the same donor patient. To date, these infusions have generally been well tolerated according to the investigators involved with their administration.
Unfortunately, standardization of donor units according to anti-Ebola antibody titers, including neutralizing activity, has not occurred on a uniform basis and, in the case of the most frequent plasma donor, plasma has been obtained from different points in the convalescence period. A reliable, consistent, and well-characterized source of plasma, or even better intravenous immune globulin, would be required for a robust evaluation of this strategy. In this regard, it was suggested that postimmunization plasma harvested from individuals who have received the current Ebola vaccines currently in phase 1 and early phase 2 testing might conceivably be an acceptable alternative to convalescent plasma given its expected abundance and relative ease of procurement from normal volunteer vaccine recipients. However, from the standpoint of a broadly protective response in individuals with established infection, it could also be argued that the more restricted, likely oligoclonal, antibody response generated by these GP-based vaccines may or may not be comparable to the broader polyclonal response induced by natural infection and presumably present in convalescent plasma. The current vaccine trials are actively evaluating the degree of both humoral and cell-mediated immunity induced by the 2 major vaccine constructs under study, and consideration should be given to evaluating plasma from vaccine recipients in a postexposure prophylaxis model. These 2 top choices recommended for research prioritization in an RCT are obviously immune-based approaches, a strategy for which there is substantial precedent but minimal success in other viral diseases. The investigator group briefly also touched upon the issue of which of the available directly acting antiviral agents under consideration might be recommended as the third or fourth category of agents to be entered into such a study. As part of this consideration, the route of administration (oral vs parenteral; injection vs infusion) was felt be a significant factor. At the time of the workshop, no single agent was uniquely identified for prioritization, and clearly more discussion of this topic is warranted in the very near term as additional data emerge. Subsequent to the last meeting, Tekmira announced plans to deploy an siRNA product tailored for the EBOV strain in Guinea [27] .
The urgency of mounting an effective response to the EVD outbreak has catalyzed a reexamination of the entire process by which medical countermeasures against BSL-4 pathogens are developed, regulated, manufactured, and deployed. Hopefully, the lessons learned here will facilitate MCM development for other BSL-4 pathogens in the future. Participants in the recent NICBR-sponsored workshops agreed that organized focus sessions of this type are essential to foster open communication among scientists, biotechnology companies, and government agencies. The need for such focused workshops will accelerate in tandem with the unprecedented number of recent breakthroughs in the development of MCMs for high-consequence pathogens. Through this process, lead candidates would be advanced expeditiously and made available to laboratory workers, healthcare workers, responders to periodic outbreaks, and eventually to EVD patients worldwide. 
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